Patents by Inventor Shinji Kagaya

Shinji Kagaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11041014
    Abstract: The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 22, 2021
    Assignee: S & K Biopharma, Inc.
    Inventors: Atsushi Sato, Shinji Kagaya
  • Publication number: 20210169991
    Abstract: The purpose of the present invention is to develop a medicine for diseases related to glycosaminoglycan functions with less side effects. Provided is a glycosaminoglycan inhibitor or promoter that comprises lactoferrin or a derivative thereof.
    Type: Application
    Filed: December 17, 2020
    Publication date: June 10, 2021
    Inventors: Masao NAKAMURA, Atsushi SATO, Shinji KAGAYA
  • Patent number: 10562959
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or(Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 18, 2020
    Assignee: NRL PHARMA, INC.
    Inventors: Atsushi Sato, Shinji Kagaya
  • Publication number: 20190309049
    Abstract: The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 10, 2019
    Applicant: NRL PHARMA, INC.
    Inventors: Atsushi SATO, Shinji KAGAYA
  • Publication number: 20180072794
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Application
    Filed: September 29, 2017
    Publication date: March 15, 2018
    Applicant: NRL PHARMA, INC.
    Inventors: Atsushi SATO, Shinji KAGAYA
  • Patent number: 9809641
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: November 7, 2017
    Assignee: NRL PHARMA, INC.
    Inventors: Atsushi Sato, Shinji Kagaya
  • Publication number: 20170296629
    Abstract: An object of the present invention is to provide a novel drug inhibiting extracellular trap formation in leukocytes. The present invention provides an inhibitor of extracellular trap formation in leukocytes containing a lactoferrin fragment, and a composition containing lactoferrin for treating a disease related to the extracellular trap formation in leukocytes.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 19, 2017
    Applicants: KEIO UNIVERSITY, NRL PHARMA, INC.
    Inventors: Junichi HIRAHASHI, Koshu OKUBO, Hiroshi KAWAKAMI, Shinji KAGAYA
  • Publication number: 20160067315
    Abstract: The present invention has an object of providing a novel drug inhibiting formation of leukocyte extracellular traps. The present invention provides a lactoferrin-containing inhibitor of formation of leukocyte extracellular traps, and a lactoferrin-containing composition for treating a disease associated with the formation of the leukocyte extracellular traps.
    Type: Application
    Filed: April 8, 2014
    Publication date: March 10, 2016
    Inventors: Junichi HIRAHASHI, Yasuteru URANO, Koushu OKUBO, Mako KAMIYA, Shinji KAGAYA
  • Publication number: 20150093382
    Abstract: The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by: (LF-s-Y)n or (Y-s-LF)n [wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, Y represents the protein or peptide comprising an FcRn-binding region, s represents any amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 2, 2015
    Inventors: Atsushi Sato, Shinji Kagaya
  • Patent number: 7172867
    Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: February 6, 2007
    Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
  • Patent number: 7115373
    Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: October 3, 2006
    Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center For Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
  • Publication number: 20040234969
    Abstract: CYP1B1 was obtained as a gene whose expression levels in mononuclear cells greatly differs between a steroid responder group and a poorly steroid responder group of atopic dermatitis patients. CYP1B1 is a gene whose expression levels are reduced in mononuclear cells of the poorly steroid responder group. The present invention provides a method for testing steroid responsiveness and a method of screening for a compound that is useful in improving steroid responsiveness using the expression level of this gene in biological samples as an indicator.
    Type: Application
    Filed: May 19, 2004
    Publication date: November 25, 2004
    Inventors: Sugita Yuji, Masayuki Heishi, Shinji Kagaya, Shigemichi Gunji, Hiroshisa Saito
  • Publication number: 20040214192
    Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
    Type: Application
    Filed: June 27, 2003
    Publication date: October 28, 2004
    Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
  • Publication number: 20040214231
    Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.
    Type: Application
    Filed: July 1, 2003
    Publication date: October 28, 2004
    Applicants: Genox Research, Inc., Japan as Rep. by General Director of Agency of National Center for Child Health and Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
  • Publication number: 20040197786
    Abstract: RING6 and HLA-DMB are described herein as genes whose expression levels in mononuclear cells greatly differ between a steroid responder group and a poor steroid responder group in atopic dermatitis patients. Specifically, the expression levels of the RING6 and HLA-DMB genes were demonstrated to be reduced in steroid-responsive patients. Using the expression level of such genes in biological samples as markers of steroid responsiveness, the present invention provides a method of testing for steroid responsiveness and a method of screening for compounds that may be used to improve steroid responsiveness.
    Type: Application
    Filed: May 25, 2004
    Publication date: October 7, 2004
    Inventors: Yuji Sugita, Masayuki Heishi, Shinji Kagaya, Shigemichi Gunji, Gozoh Tsujimoto